Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Mar;98(3):253-9.
doi: 10.1111/j.1742-7843.2006.pto_293.x.

Indications for propensity scores and review of their use in pharmacoepidemiology

Affiliations
Review

Indications for propensity scores and review of their use in pharmacoepidemiology

Robert J Glynn et al. Basic Clin Pharmacol Toxicol. 2006 Mar.

Abstract

Use of propensity scores to identify and control for confounding in observational studies that relate medications to outcomes has increased substantially in recent years. However, it remains unclear whether, and if so when, use of propensity scores provides estimates of drug effects that are less biased than those obtained from conventional multivariate models. In the great majority of published studies that have used both approaches, estimated effects from propensity score and regression methods have been similar. Simulation studies further suggest comparable performance of the two approaches in many settings. We discuss five reasons that favour use of propensity scores: the value of focus on indications for drug use; optimal matching strategies from alternative designs; improved control of confounding with scarce outcomes; ability to identify interactions between propensity of treatment and drug effects on outcomes; and correction for unobserved confounders via propensity score calibration. We describe alternative approaches to estimate and implement propensity scores and the limitations of the C-statistic for evaluation. Use of propensity scores will not correct biases from unmeasured confounders, but can aid in understanding determinants of drug use and lead to improved estimates of drug effects in some settings.

PubMed Disclaimer

Figures

None
Frequency of Publications Using Propensity Score Methods by Year
Figure 2
Figure 2. The non-overlap of the exposure propensity score distribution among treated and untreated study subjects
In this example subjects with very low propensity score are never treated while subjects with very high propensity score are all treated.
None
Distribution of the propensity score
None
Propensity Score Calibration

References

    1. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327–333. - PubMed
    1. Drake C. Effects of misspecification of the propensity score on estimators of treatment effect. Biometrics. 1993;49:1231–1236.
    1. Miettinen OS. Stratification by a multivariate confounder score. Am J Epidemiol. 1976;104:609–620. - PubMed
    1. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet. 2002;359:118–123. - PubMed
    1. Pike MC, Anderson J, Day N. Some insights into Miettinen’s multivariate confounder score approach to case-control study analysis. Epidemiol Comm Health. 1979;33:104–106. - PMC - PubMed

Publication types